AMD3100, in combination with or not with anti-PD-L1 antibodies, has been applied in immunotherapeutic against CRC, pancreatic cancer, hepatocellular carcinoma, and breast cancer (15, 16, 33, 34). Here, CD274 is linked to breast carcinoma.